Hengrui Medicine controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2020
Sales staff involvement in doctor bribery case raises concerns over pharmaceutical promotion compliance
In May 2020, Securities Times reported that a judgment in a doctor bribery case involved cash transactions between sales staff of a Hengrui Medicine subsidiary and hospital personnel. Hengrui responded that it was the personal conduct of subsidiary employees, the relevant personnel had left, and responsible leaders were reassigned. The incident sparked discussion on pharmaceutical promotion compliance and does not determine that all academic promotion expenses constitute bribery.
2020
Hengrui responds to media questions about subsidiary employee bribery case and sales expenses
Company response
Hengrui Pharmaceutical said a subsidiary employee's conduct in a bribery case involving a doctor at a Zhejiang hospital seriously violated company rules and exposed management gaps. It said the relevant personnel had left and the subsidiary's responsible leader had been transferred from the post, and said it would strengthen compliance management of subsidiaries. The company also responded to media questions about sales expenses.
Company response
Personnel action — 恒瑞医药
目前，相关人员已离职，子公司责任领导已被调离岗位。
Remediation — 恒瑞医药
今后，公司将吸取教训，加强对子公司的合规管理，杜绝此类事情发生。
Source excerpt
恒瑞医药(600276)5月12日晚间发布公告回应媒体质疑。公司表示，浙江某医院医生受贿案事件是子公司员工个人行为，严重违反了公司管理制度，但也反映出公司管理方面存在漏洞。目前，相关人员已离职，子公司责任领导已被调离岗位。今后，公司将吸取教训，加强对子公司的合规管理，杜绝此类事情发生。
公司表示，浙江某医院医生受贿案事件是子公司员工个人行为，严重违反了公司管理制度，但也反映出公司管理方面存在漏洞。
今后，公司将吸取教训，加强对子公司的合规管理，杜绝此类事情发生。